月度归档： 2026 年 5 月

PARP inhibitors are built on the idea of exploiting weaknesses in how tumor cells repair DNA. Among the different repair systems, PARP (poly ADP-ribose polymerase) enzymes are involved in fixing single-strand DNA breaks. When PARP detects damage, it binds to DNA and recruits other repair proteins to resolve it. 

Atopic dermatitis is a chronic, relapsing inflammatory skin disorder characterized by eczematous lesions and intense itchiness, which can substantially impair an individual’s quality of life. Over the past decade, advances in immunological understanding – particularly the central role of type 2 inflammation, an immune response that frequently overreacts to allergens – have driven a therapeutic shift from broad immunosuppression toward more targeted, mechanism-based interventions. While established treatments have significantly improved people’s ability to control their symptoms, many patients remain inadequately treated due to the disease’s persistent nature. This highlights the need for additional options, and, consequently, a diverse pipeline of new atopic dermatitis treatments is currently under investigation, spanning both validated pathways and novel immunological targets. 

The past year saw a string of pipeline cuts and downsizing plans strike the biotech job market. Have layoffs spooked young professionals looking for a way into the industry, and does the employment landscape seem to be looking up this year?

Discovered just over a decade ago, CRISPR has revolutionized the biomedical industry thanks to the fact it allows scientists to target diseases – particularly genetic ones – that were previously untreatable by making direct edits to genes. However, despite being versatile, CRISPR has limitations – while it is ideal for breaking problematic genes and making small edits, it is not very useful when it comes to inserting whole genes or large chunks of DNA. Now, though, the recent discovery of a molecular oddity known as bridge RNA, found in bacteria, could lead to a new gene editing technique that can overcome these limitations.

RNA editing has recently made significant progress as a potentially safer alternative to gene editing for treating a number of genetic diseases. In December 2023, patients were dosed in the first-ever clinical trial for an RNA editing candidate – a milestone achievement that could see RNA editing take off in the coming months. 

Florida-based Catalyst markets rare neuromuscular and neurological disease treatments that generated sales of $589 milli…